Abstract:
:Imatinib is a tyrosine kinase inhibitor and is now used regularly in chronic myeloid leukaemia therapy in chronic phase with great success. This drug due its very nature of action is suspected to be teratogenic hence the patients are counseled not to get pregnant while on this drug. However in world literature few normal pregnancies have been reported in patients on Imatinib therapy, though no twin pregnancy has been reported on this medication. We report here the birth of normal mono-ovular mono-chorionic twin while the patient is on imatinib during conception and early pregnancy for chronic myeloid leukaemia.
journal_name
Leuk Resjournal_title
Leukemia researchauthors
Meera V,Jijina F,Shrikande M,Madkaikar M,Ghosh Kdoi
10.1016/j.leukres.2008.03.007subject
Has Abstractpub_date
2008-10-01 00:00:00pages
1620-2issue
10eissn
0145-2126issn
1873-5835pii
S0145-2126(08)00145-8journal_volume
32pub_type
杂志文章abstract::To elucidate the biological characteristics of chronic myelogenous leukemia (CML) cells, we observed morphological and functional changes of CML cells during primary long-term culture, in which their morphology changed to that of myofibroblasts with similar molecular characteristics to the parental CML cells including...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2010.09.019
更新日期:2011-05-01 00:00:00
abstract::We studied differentiation inducing effects of retinoic acid (RA), 1 alpha, 25-dihydroxyvitamin D3 (D3) and interferons (IFNs), alone and in combination, on fresh myeloid leukemic cells from 8 patients. RA not only induced the differentiation of leukemic cells in 5/8 cases, but potentiated differentiation by IFNs eith...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(90)90072-h
更新日期:1990-01-01 00:00:00
abstract::The peripheral blood lymphocyte to monocyte ratio (LMR) at diagnosis has been used to predict survival in diffuse large B-cell lymphoma (DLBCL) patients, but its prognostic significance with respect to different cell-of-origin (COO) subtypes remains unknown. We retrospectively analyzed 168 de novo DLBCL patients in th...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2014.03.013
更新日期:2014-06-01 00:00:00
abstract::Pycnogenol, rich of many phytochemicals of medical value, is a commercialized nutrient supplement extracted from the bark of European coastal pine. In this study, we investigated the anti-tumor effects of Pycnogenol on HL-60, U937 and K562 human leukemia cell lines. We found that Pycnogenol inhibited cell proliferatio...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2004.10.006
更新日期:2005-06-01 00:00:00
abstract::A permanent cell line, MN 60, was established from the peripheral blood of a patient with an acute lymphoblastic leukemia (ALL) classified morphologically as being of the L3 type. Cell growth started rapidly in vitro and no feeder cells were needed. Cells of the MN-60 line were identical to the original leukemic cells...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(82)90085-6
更新日期:1982-01-01 00:00:00
abstract::Checkpoint genes code for a family of proteins which sense DNA damage in eukaryotic cells. They play an important role in the control of the cell cycle. The human CHK2 is a homolog of the yeast G(2) checkpoint kinases known as CDS1 and RAD53. The CHK2 may be a tumor suppressor gene because it was found to be mutated i...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/s0145-2126(00)00130-2
更新日期:2001-04-01 00:00:00
abstract::To improve the recovery rate of high-risk patients with acute promyelocytic leukemia (APL), we used all-trans retinoic acid (ATRA)/arsenic trioxide (ATO)/daunorubicin combination in remission induction, daunorubicin and cytarabine in consolidation, and ATRA/ATO/methotrexate ± 6-mercaptopurine in maintenance treatment ...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2012.03.027
更新日期:2012-07-01 00:00:00
abstract::An acute promyelocytic leukemia in the rat (BNML) has been used in model studies on pathogenesis and therapy of human acute myeloid leukemia. The blood supply to bone marrow during BNML development has hitherto not been examined, even though in general, blood flow to hematopoietic tissues might affect drug treatment a...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(93)90071-r
更新日期:1993-08-01 00:00:00
abstract::Myelodysplastic syndrome (MDS) in children has been reported to be associated with various constitutional anomalies; however, it has not been described previously in patients with Griscelli syndrome (GS). In this report, we present a case with GS and refractory anemia with an excess of blasts. We believe that careful ...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/s0145-2126(98)00075-7
更新日期:1998-09-01 00:00:00
abstract::Blastic transformation of myeloproliferative neoplasms (MPN) is still poorly understood. We describe a cohort of 23 Roswell Park Cancer Institute (RPCI) patients and 89 additional cases from the English literature for whom biologic features were described. We initially compared our 23 patients to the 89 cases from the...
journal_title:Leukemia research
pub_type: 杂志文章,评审
doi:10.1016/j.leukres.2010.07.031
更新日期:2011-05-01 00:00:00
abstract::We described the clinical features and outcomes for 63 adult patients with acute myeloid leukemia (AML) with a translocation involving the 11q23 locus (MLL) who were treated at Memorial Sloan Kettering Cancer Center (MSK). The population included 40 female (63 %) and 23 male (37 %) patients, with a median age of 51 ye...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2020.106453
更新日期:2020-11-01 00:00:00
abstract::Febrile neutropenia (FN) risk-assessment and granulocyte-colony stimulating factor (G-CSF) prophylaxis use in clinical practice was evaluated in patients with diffuse large B-cell lymphoma receiving R-CHOP-21. More G-CSF primary prophylaxis was used in patients assessed as high FN risk, but R-CHOP-21 was associated wi...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2012.02.002
更新日期:2012-05-01 00:00:00
abstract::We have established a new T-cell line (CL-8313) that produces interleukin-3 from the spleen cells of mice with a radiation-induced myeloproliferative disorder. IL-3 activity was detected at an extremely high level in the culture medium of the CL-8313 cell line in the absence of any exogenous stimulator. A large amount...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(88)90005-7
更新日期:1988-01-01 00:00:00
abstract::Overexpression of the Wilms' tumor gene 1 (WT1) was observed in most leukemia cells. In addition to four major isoforms of WT1, an N-terminally truncated isoforms (sWT1) has been identified. We separately quantified the transcript levels of sWT1 and full-length WT1 (fWT1) in 237 patients with acute myeloid leukemia (A...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2011.01.002
更新日期:2011-05-01 00:00:00
abstract::Inosine 5'-monophosphate (IMP) dehydrogenase catalyzes the rate-limiting reaction of guanine nucleotide biosynthesis and has been implicated in the reaction of cell growth and differentiation. We investigated the ability of mycophenolate mofetil, a prodrug of mycophenolic acid, to induce differentiation in HL-60 and U...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/s0145-2126(00)00045-x
更新日期:2000-09-01 00:00:00
abstract::Leukemic cell lines have become important tools for studies of disease providing a monoclonal cell population that can be extensively expanded in vitro while preserving leukemic cellular characteristics. However, studies of chronic lymphocytic leukemia (CLL) have been impeded in part by the lack of continuous human ce...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2015.10.008
更新日期:2016-01-01 00:00:00
abstract::Secondary acute lymphoblastic leukemia (s-ALL) is rare and poorly defined and data regarding outcomes post-transplant are lacking. Here, we report a detailed analysis of s-ALL at our Institution. Among 211 eligible patients with ALL from 2006 to 2017, 30 (14%) were defined as s-ALL and the remaining as primary ALL (p-...
journal_title:Leukemia research
pub_type: 杂志文章,meta分析,评审
doi:10.1016/j.leukres.2018.07.024
更新日期:2018-09-01 00:00:00
abstract::Activating mutations of Fms-like tyrosine kinase 3 (Flt3) are the most common genetic abnormalities found in acute myeloid leukemia (AML) and represent potential therapeutic targets. The novel Flt3 inhibitor KRN383 inhibited the autophosphorylation of Flt3 bearing internal tandem duplications (ITDs) and the Asp835Tyr ...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2006.02.028
更新日期:2006-12-01 00:00:00
abstract::A single somatic mutation, V617F, in the pseudokinase domain of the Jak2 is the primary cause of many chronic myeloproliferative diseases. As valine 617 of Jak2 is conserved as valine 678 of Tyk2, we examined the effect of a homologous mutation in Tyk2 (V678F Tyk2) on cell growth. V678F Tyk2 augmented the transcriptio...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2006.08.018
更新日期:2007-08-01 00:00:00
abstract::In a recent phase I study, a combination of gemcitabine at 10 mg/(m(2)min) for 12 h and mitoxantrone 12 mg/m(2) daily for 3 days, achieved a complete remission (CR) in 3 of 12 (25%) patients with refractory leukemia. A pilot assessment of this regimen was conducted to determine its tolerability in patients with refrac...
journal_title:Leukemia research
pub_type: 临床试验,杂志文章
doi:10.1016/s0145-2126(02)00171-6
更新日期:2003-04-01 00:00:00
abstract::Despite high rates of hematologic and cytogenetic responses to imatinib therapy, the emergence of resistance to imatinib has been recognized as a major problem in the treatment of Ph-positive leukemia. The high frequency of BCR-ABL mutations and amplifications represents the high degree of heterogeneity in patients wi...
journal_title:Leukemia research
pub_type: 杂志文章,评审
doi:10.1016/j.leukres.2003.10.007
更新日期:2004-05-01 00:00:00
abstract::Chronic Lymphocytic Leukemia B cells (CLL) are malignant cells which retain at least some functions of normal B cells. Paramount amongst the latter is that when such cells are appropriately stimulated, they are able to present antigens, including any potential tumor antigens, making them excellent choices as a candida...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2018.03.002
更新日期:2018-05-01 00:00:00
abstract::Although recent advances in chemotherapy have markedly improved outcome of acute lymphoblastic leukemia (ALL), infantile ALL with MLL gene rearrangements (MLL+ALL) is refractory to chemotherapy. We have shown that specific cytokines FLT3 ligand and TGFβ1 both of which are produced from bone marrow stromal cells synerg...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2018.11.001
更新日期:2018-12-01 00:00:00
abstract::Mantle cell lymphoma (MCL) an incurable B-cell, non-Hodgkin lymphoma (NHL) urgently requires new treatments. We assessed reovirus mediated oncolysis in a panel of human MCL cell lines. In vitro, we found the cytopathic effect of reovirus infection ranged from high to very limited and correlated with levels of Ras acti...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2009.05.020
更新日期:2010-01-01 00:00:00
abstract::Model cell lines are essential tools for investigating the biology and therapeutics of cancer. Approximately 1500 human hematopoietic neoplastic cell lines have been described, covering most major disease entities. Waldenström's macroglobulinemia (WM) is a rare incurable hematological neoplasm from which only three ce...
journal_title:Leukemia research
pub_type: 杂志文章,评审
doi:10.1016/j.leukres.2008.04.016
更新日期:2008-11-01 00:00:00
abstract:BACKGROUND:Little is known on racial differences in patients with diffuse large B-cell lymphoma (DLBCL). The aim of this retrospective study is to compare characteristics, prognostic factors and outcomes of Asian and Western patients with DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine and pred...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2013.01.002
更新日期:2013-04-01 00:00:00
abstract:BACKGROUND:T- cell prolymphocytic leukemia (T- PLL) is a rare aggressive hematological malignancy. Alemtuzumab, an anti-CD52 humanized monoclonal antibody, is the treatment of choice for remission induction. Allogeneic hematopoietic cell transplantation (allo-HCT) has been described to induce durable remissions and imp...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2018.01.009
更新日期:2018-04-01 00:00:00
abstract::Activating mutations of the c-kit gene are frequently found in CBF (core binding factor) leukemias. We evaluated the effect of tyrosine kinase inhibitor dasatinib in leukemic cell lines bearing or not c-kit mutations. Our data demonstrate that in the AML Kasumi-1 cell line, bearing the N822K c-kit mutation, dasatinib ...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2012.10.011
更新日期:2013-02-01 00:00:00
abstract::Peripheral blood and/or bone marrow lymphoblasts from 25 patients with acute lymphoblastic leukemia (ALL) were tested with a panel of monoclonal antibodies (MoAbs) and conventional hematopoietic markers by three different laboratories. The results were analysed to evaluate the reproducibility of ALL phenotype determin...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(86)90083-4
更新日期:1986-01-01 00:00:00
abstract::The efficiency of gene transfer into human leukemia cell lines by electroporation was investigated. For both transient expression (beta-galactosidase gene) and stable transformation (neomycin resistance gene), the transfer efficiency into leukemia cell lines using a square wave pulse was superior to that using an expo...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(91)90062-x
更新日期:1991-01-01 00:00:00